TOP TEN perturbations for P10412 (Homo sapiens)

Organism: Homo sapiens
Gene: P10412
Selected probe(set): 208553_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P10412 (208553_at) across 5610 perturbations tested by GENEVESTIGATOR:

SP-C (L188Q) overexpr. study 1 / SP-C (wt) overexpr. study 1

Relative Expression (log2-ratio):-4.8643713
Number of Samples:3 / 3
Experimental SP-C (L188Q) overexpr. study 1
HEK293 cells transiently overexpressing L188Q-mutated surfactant protein C : SP-C (L188Q). SP-C mutations are associated with interstitial lung diseases (ILD).
Control SP-C (wt) overexpr. study 1
HEK293 cells transiently overexpressing wild-type surfactant protein C: SP-C (Wt).

sangivamycin study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):3.1512394
Number of Samples:2 / 2
Experimental sangivamycin study 1
MCF7 cells treated with 2uM sangivamycin for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

adrenal gland cancer study 4 / normal adrenal cortex tissue

Relative Expression (log2-ratio):2.7788486
Number of Samples:43 / 4
Experimental adrenal gland cancer study 4
Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC).
Control normal adrenal cortex tissue
Histological normal adrenal gland cortical tissue samples derived after autopsy.

precursor-B-ALL study 7 (PDX; long-term; >10wk) / precursor-B-ALL study 7 (late relapse; >24m)

Relative Expression (log2-ratio):-2.7717476
Number of Samples:7 / 8
Experimental precursor-B-ALL study 7 (PDX; long-term; >10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia generated in NOD/SCID mice with time to manifestation of leukemia (TTL) more than 10 weeks (long-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with precursor BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene; remision at day 33; non-high risk group; late relapse group (relapse after 24 months from diagnosis).
Control precursor-B-ALL study 7 (late relapse; >24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse after 24 months from diagnosis (late relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

precursor-B-ALL study 3 (MLL-rearranged) / precursor-B-ALL study 3 (BCR-ABL)

Relative Expression (log2-ratio):2.6376238
Number of Samples:5 / 4
Experimental precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (BCR-ABL)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 7 (PDX; short-term; <10wk) / precursor-B-ALL study 7 (early relapse; <24m)

Relative Expression (log2-ratio):-2.5415974
Number of Samples:5 / 22
Experimental precursor-B-ALL study 7 (PDX; short-term; <10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia (B-ALL) generated in NOD/SCID mice with time to manifestation of leukemia (TTL) less than 10 weeks (short-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene,;remision at day 33; non-high risk group; early relapse group (relapse within 24 months from diagnosis).
Control precursor-B-ALL study 7 (early relapse; <24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse within 24 months after diagnosis (early relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

B-CLL study 9 (CD19+; CD5+; Wnt3a) / B-CLL study 9 (CD19+; CD5+)

Relative Expression (log2-ratio):-2.5375223
Number of Samples:6 / 172
Experimental B-CLL study 9 (CD19+; CD5+; Wnt3a)
CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and treated with Wnt3a for 48 hours. It is not clear whether the concentration of Wnt3a was 5ng/ml or 50ng/ml. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control B-CLL study 9 (CD19+; CD5+)
CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL). B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.

sulindac study 4 (3000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.2903204
Number of Samples:2 / 2
Experimental sulindac study 4 (3000uM)
Hepatocytes treated with compound: sulindac (3000uM; CHEMBL15770) for 8 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 8 hours.

Wnt3a study 1 / normal B-cell sample (CD19+)

Relative Expression (log2-ratio):-2.2506914
Number of Samples:4 / 20
Experimental Wnt3a study 1
CD19+ B-cell samples from normal control subjects and treated with Wnt3a for 48 hours. It is not clear whether the concentration of Wnt3a was 5ng/ml or 50ng/ml. B-cells were isolated from peripheral blood mononuclear cells and cultured in B-cell media.
Control normal B-cell sample (CD19+)
CD19+ B-cell samples from normal control subjects. B-cells were isolated from peripheral blood mononuclear cells.

colchicine study 7 (4000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):2.2074852
Number of Samples:2 / 2
Experimental colchicine study 7 (4000uM)
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.